Table 8 Clinical and hemodynamic effect of BPA treatment in 24 CTEPH patients
| Â | 24 CTEPH patients | p | |
|---|---|---|---|
Before BPA | After BPA | ||
Patient characteristics | |||
 Age (years) | 59 ± 10 | – | |
 Female (%) | 18 (75%) | – | |
 Number of BPA sessions/patient | 3 (2,4) | – | |
 Duration to follow-up (days) | 115 (81, 177) | – | |
 PAH targeted therapy (%) | 11 (45.8%) |  | |
Hemodynamics | |||
 Heart rate | 79.8 ± 15.3 | 69.5 ± 10.1 | 0.009 |
 Mean RAP (mmHg) | 7.9 ± 4.0 | 5.5 ± 3.4 | 0.062 |
 Systolic PAP (mmHg) | 70.8 ± 25.0 | 50.3 ± 14.2 | 0.001 |
 Diastolic PAP (mmHg) | 23.5 ± 9.1 | 15.8 ± 6.0 | 0.001 |
 Mean PAP (mmHg) | 40.6 ± 13.8 | 28.5 ± 8.0 | 0.001 |
 PVR (Wood unit) | 8.0 (3.7,17.0) | 4.0 (2.9, 5.4) | 0.007 |
 Cardiac output (L/min) | 3.5 (2.6, 5.4) | 4.7 (3.7, 5.8) | 0.017 |
 Cardiac index (L/min/m2) | 2.2 (1.8, 3.4) | 2.9 (2.5, 3.5) | 0.044 |
 PASO2 (%) | 64.1 ± 9.5 | 68.7 ± 7.2 | 0.068 |
 MVSO2 (%) | 93.7 ± 3.4 | 95.2 ± 3.0 | 0.116 |
 NT-proBNP (pg/ml) | 171.0 (71.5, 1569.0) | 50.6 (26.5, 113.4) | 0.002 |
Exercise capacity | |||
 WHO functional class (I–II/III–IV, %) | 50.0%/50.0% | 95.8%/4.2% | < 0.001 |
 Absolute change of 6MWD (meters) | 88.0 ± 55.5 | < 0.001 | |